2026 Volume: 02 Issue: 06 www.ijrpa.com ISSN 2456-9995 Review Article

International Journal Research Publication Analysis

Page: 01-12

DIFFERENT TYPES OF DRUG DELIVERY SYSTEMS AND THEIR IMPORTANCE IN MODERN THERAPEUTICS: A COMPREHENSIVE REVIEW

Abhinav Saini*, Anju Bala, Rohit Chandel

Institute of Pharmaceutical Sciences, IET Bhaddal Punjab, India.

Article Received: 6 May 2026
Article Revised: 26 May 2026
Published on: 16 June 2026

***Corresponding Author: Abhinav Saini**
Institute of Pharmaceutical Sciences, IET Bhaddal Punjab, India.

DOI: https://doi-doi.org/101555/ijrpa.4379

ABSTRACT

The therapeutic success of a pharmaceutical agent is determined not only by its pharmacodynamic and pharmacokinetic properties but also by the efficiency of its delivery to the intended biological target. Drug delivery systems (DDS) have therefore become an essential component of modern pharmaceutical science, aiming to enhance drug efficacy, reduce toxicity, and improve patient compliance. Conventional drug delivery methods often suffer from limitations such as poor bioavailability, non-specific distribution, rapid clearance, and frequent dosing requirements. In response, significant advances have been made in the development of controlled, targeted, and novel drug delivery systems utilizing polymers, nanotechnology, biomaterials, and biotechnology-based approaches. This review provides an in-depth and critical discussion of various drug delivery systems, including conventional systems, controlled and sustained release formulations, targeted delivery systems, transdermal, pulmonary, ocular, gastrointestinal, mucoadhesive, implantable, gene-based, vaccine, and nanotechnology-driven drug delivery platforms. The mechanisms, advantages, limitations, and clinical significance of each system are examined. Regulatory challenges, translational barriers, and future prospects of drug delivery technologies are also highlighted. This review aims to serve as a comprehensive reference for researchers, academicians, and pharmaceutical scientists involved in drug delivery research and development.

KEYWORDS: Drug delivery systems; Controlled release; Targeted drug delivery; Nanotechnology; Novel drug delivery; Pharmaceutical sciences.

1. INTRODUCTION

Drug delivery systems constitute the interface between a pharmaceutical formulation and the biological system, playing a pivotal role in determining therapeutic outcomes. Historically, drug discovery efforts focused primarily on identifying potent active pharmaceutical ingredients (APIs), while formulation strategies were often secondary considerations. However, it is now widely acknowledged that the effectiveness of a drug is profoundly influenced by how it is delivered to the body and, more importantly, to its site of action [1].

Conventional dosage forms such as tablets, capsules, syrups, injections, and topical formulations continue to dominate clinical practice due to their simplicity and cost-effectiveness. Nevertheless, these systems frequently exhibit significant drawbacks, including fluctuating plasma drug concentrations, low bioavailability, systemic toxicity, and poor patient adherence, particularly in chronic therapies [2]. These limitations become even more pronounced with modern drug molecules such as peptides, proteins, monoclonal antibodies, and nucleic acids, which are often unstable and poorly absorbed when administered using traditional methods [3].

Drug delivery systems have evolved as a response to these challenges, with the primary objectives of optimizing drug release profiles, improving site-specific targeting, minimizing adverse effects, and enhancing patient compliance. Advances in polymer science, nanotechnology, molecular biology, and biomedical engineering have enabled the development of sophisticated DDS capable of controlled, sustained, and stimuli-responsive drug release [4].

In the era of personalized medicine, DDS are increasingly designed to account for patient-specific factors, disease pathology, and molecular targets. The integration of drug delivery with diagnostic and therapeutic functions, often referred to as “theranostics,” further underscores the growing importance of DDS in modern healthcare [5]. This review systematically explores the different types of drug delivery systems and critically evaluates their importance in contemporary therapeutics.

2. Conventional Drug Delivery Systems

Conventional drug delivery systems represent the earliest and most widely utilized methods of drug administration. These systems include oral solid dosage forms, liquid preparations, parenteral injections, and topical formulations. Despite their extensive use, conventional DDS provide limited control over drug release and distribution within the body [6].

2.1 Oral Drug Delivery Systems

Oral administration is the most preferred route due to its convenience, safety, and high patient acceptability. Tablets and capsules account for a substantial proportion of marketed pharmaceutical products. However, oral drug delivery is often associated with challenges such as degradation of drugs in the acidic gastric environment, enzymatic metabolism, poor solubility, and first-pass hepatic metabolism, which collectively reduce bioavailability [7].

Many drugs require frequent dosing to maintain therapeutic plasma concentrations, leading to poor patient adherence, particularly in long-term therapies. Additionally, interindividual variability in gastrointestinal physiology can result in unpredictable drug absorption and therapeutic outcomes [8].

2.2 Parenteral Drug Delivery Systems

Parenteral administration, including intravenous, intramuscular, and subcutaneous routes, bypasses the gastrointestinal tract and provides rapid onset of action with complete bioavailability. These systems are particularly useful for emergency treatments and drugs that are poorly absorbed orally [9].

However, parenteral drug delivery is invasive, often painful, and associated with risks such as infection, thrombosis, and patient discomfort. Long-term parenteral therapy is generally impractical, further emphasizing the need for alternative delivery strategies [10].

2.3 Topical Drug Delivery Systems

Topical formulations such as creams, ointments, gels, and lotions are primarily used for localized drug action. While they reduce systemic exposure and associated side effects, drug penetration across biological barriers such as the skin remains a significant limitation [11].

Overall, the shortcomings of conventional drug delivery systems have driven the development of advanced DDS aimed at improving therapeutic efficacy and patient outcomes.

3. Controlled and Sustained Release Drug Delivery Systems

Controlled and sustained release drug delivery systems were developed to address the limitations of conventional immediate-release formulations. These systems are designed to release drugs at a controlled rate over an extended period, maintaining plasma drug concentrations within the therapeutic window [12].

Sustained release formulations prolong drug action by slowing drug release, thereby reducing dosing frequency. Controlled release systems provide a more precise release profile, often independent of physiological variables such as pH and gastrointestinal motility [13].

Polymeric matrices, reservoir systems, osmotic pumps, and biodegradable implants are commonly employed in controlled release DDS. These systems have demonstrated significant benefits in the management of chronic diseases such as hypertension, diabetes, arthritis, and neurological disorders [14].

Despite their advantages, controlled release systems present challenges related to complex formulation design, manufacturing scalability, and the risk of dose dumping. Nevertheless, their ability to improve patient compliance and therapeutic consistency underscores their importance in modern pharmacotherapy [15].

4. Targeted Drug Delivery Systems

Targeted drug delivery systems aim to deliver therapeutic agents selectively to specific tissues or cells, thereby enhancing efficacy while minimizing systemic toxicity. This approach is particularly critical in cancer therapy, where conventional chemotherapy often damages healthy tissues [16].

Targeting strategies are broadly classified into passive and active targeting. Passive targeting exploits physiological characteristics such as the enhanced permeability and retention (EPR) effect observed in tumor tissues [17]. Active targeting involves the use of ligands, antibodies, or peptides that bind specifically to receptors overexpressed on target cells [18].

Targeted DDS have shown promising results in oncology, gene therapy, and immunotherapy. However, challenges such as immune recognition, carrier instability, and heterogeneous target expression remain obstacles to widespread clinical translation [19].

5. Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) provide a non-invasive alternative to oral and parenteral administration. By delivering drugs across the skin into systemic circulation, TDDS bypass first-pass metabolism and offer sustained drug release [20].

Transdermal patches have been successfully used for nicotine replacement therapy, hormone replacement therapy, and pain management. However, the stratum corneum acts as a major barrier, limiting the number of drugs suitable for transdermal delivery [21].

Advanced enhancement techniques such as microneedles, iontophoresis, sonophoresis, and chemical permeation enhancers have expanded the applicability of TDDS. These innovations highlight the growing importance of transdermal systems in patient-centric drug delivery [22].

6. Pulmonary Drug Delivery Systems

Pulmonary drug delivery systems administer drugs directly to the lungs via inhalation, providing rapid onset of action and high local drug concentrations. These systems are widely used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) [23].

The pulmonary route has also been explored for systemic delivery of peptides, proteins, and vaccines due to the large surface area and extensive vascularization of the lungs [24]. However, variability in inhalation technique and pulmonary pathology can significantly affect drug deposition and therapeutic outcomes [25].

7. Ocular Drug Delivery Systems

Ocular drug delivery remains challenging due to anatomical and physiological barriers such as tear turnover, blinking, and limited permeability of ocular tissues. Conventional eye drops often result in poor bioavailability, with less than 5% of the administered dose reaching intraocular tissues [26].

Advanced ocular DDS, including in situ gels, ocular inserts, nanoparticles, and drug-eluting contact lenses, have been developed to improve drug retention and therapeutic efficacy [27]. Effective delivery to the posterior segment of the eye remains a major research focus.

8. Gastrointestinal and Mucoadhesive Drug Delivery Systems

Advanced gastrointestinal DDS aim to improve oral bioavailability and achieve site-specific drug delivery. Gastroprotective systems prolong gastric residence time, while colon-targeted systems are used for localized treatment of colonic diseases [28].

Mucoadhesive DDS adhere to mucosal surfaces, prolonging drug residence time and enhancing absorption. These systems are particularly useful in buccal, nasal, vaginal, and ocular drug delivery [29].

9. Implantable Drug Delivery Systems

Implantable DDS provide long-term, controlled drug release and are particularly beneficial for chronic diseases. These systems may be biodegradable or non-biodegradable and are commonly used in oncology and hormone therapy [30].

10. Gene, Vaccine, and Nanotechnology-Based Drug Delivery Systems

Gene and nucleic acid delivery systems enable therapeutic modulation of gene expression. Lipid nanoparticles, polymeric carriers, and viral vectors are commonly used for this purpose [31].

Nanotechnology-based DDS, including liposomes, dendrimers, polymeric nanoparticles, and micelles, have revolutionized drug delivery by enhancing solubility, stability, and targeting efficiency [32]. Advanced vaccine delivery systems such as nanoparticle-based vaccines and microneedle patches have further improved immunogenicity and patient compliance [33].

11. Regulatory Considerations and Translational Challenges

The clinical translation of advanced DDS is governed by stringent regulatory requirements related to safety, efficacy, and quality control. Regulatory agencies emphasize the need for robust characterization, reproducibility, and long-term toxicity assessment [34].

12. Future Perspectives

The future of drug delivery lies in personalized, smart, and stimuli-responsive systems. Integration of artificial intelligence, advanced biomaterials, and precision medicine approaches is expected to further transform the field [35].

13. CONCLUSION

Drug delivery systems play a central role in determining the success of modern therapeutics. The transition from conventional dosage forms to advanced, targeted, and intelligent DDS has significantly improved therapeutic efficacy, safety, and patient quality of life. Continued interdisciplinary research and regulatory support will be essential to fully realize the potential of drug delivery technologies in global healthcare.

14. Nanotechnology-Based Drug Delivery Systems

Nanotechnology-based drug delivery systems represent one of the most transformative advancements in pharmaceutical sciences. These systems utilize carriers typically ranging from 1 to 1000 nm in size to improve drug solubility, stability, bioavailability, and targeting efficiency [36]. The nanoscale dimension allows these carriers to interact more effectively with biological membranes and cellular components, enabling enhanced intracellular drug delivery.

Among the most extensively studied nanocarriers are liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, polymeric micelles, and inorganic nanoparticles. Liposomes, composed of phospholipid bilayers, can encapsulate both hydrophilic and hydrophobic drugs and have been successfully translated into clinical products such as liposomal doxorubicin [37]. Polymeric nanoparticles, fabricated from

biodegradable polymers such as polylactic acid (PLA) and poly (lactic-co-glycolic acid) (PLGA), offer controlled drug release and improved biocompatibility [38].

Dendrimers are highly branched macromolecules with well-defined architecture and surface functionality, allowing precise control over drug loading and targeting [39]. Polymeric micelles, formed from amphiphilic block copolymers, are particularly useful for delivering poorly water-soluble drugs [40]. Inorganic nanoparticles such as gold and silica nanoparticles have also gained attention due to their unique physicochemical properties and potential use in theranostic applications [41].

Despite their advantages, nanotechnology-based DDS face challenges related to large-scale manufacturing, long-term toxicity, and regulatory approval. Nevertheless, their ability to enhance therapeutic index and enable precision medicine underscores their growing importance in modern therapeutics [42].

15. Smart and Stimuli-Responsive Drug Delivery Systems

Smart or stimuli-responsive drug delivery systems are designed to release drugs in response to specific internal or external triggers such as pH, temperature, redox potential, enzymes, light, magnetic fields, or ultrasound [43]. These systems provide spatiotemporal control over drug release, minimizing off-target effects and improving therapeutic efficacy.

pH-responsive systems exploit differences between normal physiological pH and pathological environments, such as the acidic tumor microenvironment or inflamed tissues [44]. Thermo-responsive polymers release drugs in response to temperature changes, while enzyme-responsive systems utilize disease-specific enzymes to trigger drug release [45].

Externally triggered systems, including light- and magnetically responsive DDS, allow precise control over drug release using external stimuli. These systems are particularly promising in cancer therapy, where localized activation can significantly reduce systemic toxicity [46].

Although many smart DDS remain at the experimental stage, continued advances in materials science and biomedical engineering are expected to accelerate their clinical translation [47].

16. Vaccine Drug Delivery Systems

Vaccine delivery systems play a crucial role in enhancing antigen stability, immunogenicity, and patient compliance. Traditional vaccine administration via intramuscular or subcutaneous injection, while effective, is associated with limitations such as needle-associated pain, cold-chain dependence, and logistical challenges [48].

Advanced vaccine DDS include nanoparticle-based carriers, liposomal formulations, viral vectors, microneedle patches, and mucosal delivery systems. Nanoparticles enhance antigen uptake by antigen-presenting cells and promote sustained immune responses [49]. Microneedle-based vaccine delivery offers painless administration, improved stability, and the potential for self-administration [50].

Mucosal vaccine delivery through oral or nasal routes induces both systemic and mucosal immunity, which is particularly beneficial for preventing infectious diseases that enter through mucosal surfaces [51]. The rapid development and deployment of lipid nanoparticle-based mRNA vaccines during recent global health crises have highlighted the critical importance of advanced vaccine delivery technologies [52].

17. Drug Delivery Systems for Central Nervous System Disorders

Delivering drugs to the central nervous system (CNS) remains one of the most challenging aspects of drug delivery due to the presence of the blood–brain barrier (BBB). The BBB restricts the passage of most therapeutic agents, limiting treatment options for neurological disorders [53].

Advanced DDS such as nanoparticles, liposomes, and ligand-targeted carriers have been explored to facilitate drug transport across the BBB. Strategies include receptor-mediated transcytosis, adsorption-mediated transport, and intranasal drug delivery [54]. Intranasal delivery provides a non-invasive route for direct nose-to-brain transport, bypassing the BBB [55].

Effective CNS drug delivery systems hold significant promise for the treatment of neurodegenerative diseases, brain tumors, and psychiatric disorders. However, safety, targeting efficiency, and long-term effects remain critical concerns [56].

18. Comparative Evaluation of Drug Delivery Systems

A comparative assessment of different drug delivery systems highlights that no single system is universally ideal. Each DDS offers distinct advantages and limitations depending on the drug properties, disease condition, and patient requirements.

Table 1. Comparative Overview of Major Drug Delivery Systems.

Drug Delivery System	Route of Administration	Major Advantages	Key Limitations	Therapeutic Applications
Conventional DDS	Oral, Injectable	Simple, cost-effective	Poor targeting, frequent dosing	Acute therapy
Controlled Release DDS	Oral, Implant	Sustained drug levels	Complex formulation	Chronic diseases
Targeted DDS	Multiple	Reduced toxicity	High development cost	Cancer, gene therapy
Transdermal DDS	Skin	Non-invasive, steady release	Limited drug permeability	Pain, hormonal therapy
Nanotechnology-based DDS	Multiple	Enhanced bioavailability	Regulatory challenges	Oncology, vaccines

19. Regulatory and Quality Considerations

The regulatory evaluation of drug delivery systems is complex due to their multifunctional nature. Regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require comprehensive characterization of DDS, including physicochemical properties, stability, pharmacokinetics, and toxicity [57].

Nanotechnology-based DDS pose unique regulatory challenges due to their size-dependent properties and potential long-term safety concerns [58]. The adoption of Quality by Design (QbD) principles and advanced analytical techniques has improved regulatory confidence and facilitated clinical translation [59].

20. Ethical, Economic, and Global Health Considerations

While advanced DDS offer significant therapeutic benefits, ethical and economic factors must be considered. High development and manufacturing costs may limit accessibility, particularly in low- and middle-income countries [60]. Ethical considerations include patient safety, informed consent for implantable systems, and long-term environmental impact of nanomaterials [61].

Ensuring equitable access to advanced drug delivery technologies remains a global challenge that requires collaboration among policymakers, industry, and healthcare systems [62].

21. Future Directions and Emerging Trends

The future of drug delivery research is moving toward personalized, multifunctional, and intelligent systems. Integration of artificial intelligence and machine learning is expected to

optimize formulation design and predict in vivo performance [63]. Advances in 3D printing, biomaterials, and precision medicine will further expand the capabilities of DDS [64].

22. Final Conclusion

Drug delivery systems are fundamental to the success of modern therapeutics. The evolution from conventional dosage forms to advanced, targeted, and smart delivery platforms has significantly improved drug efficacy, safety, and patient adherence. Each type of DDS discussed in this review addresses specific therapeutic challenges, underscoring their collective importance in contemporary healthcare.

As pharmaceutical science continues to evolve, the role of innovative drug delivery systems will become increasingly critical in enabling personalized medicine and improving global health outcomes. Sustained interdisciplinary research, regulatory harmonization, and ethical considerations will be essential to fully realize the potential of drug delivery technologies.

REFERENCES

1. Langer R. Drug delivery and targeting. Nature. 1998;392:5–10.
2. Florence AT, Attwood D. Physicochemical principles of pharmacy. London: Pharmaceutical Press; 2016.
3. Mitragotri S, Burke PA, Langer R. Overcoming biological barriers to drug delivery. Nat Rev Drug Discov. 2014;13:655–72.
4. Peppas NA, Langer R. New challenges in biomaterials. Science. 1994;263:1715–20.
5. Torchilin VP. Multifunctional nanocarriers. Nat Rev Drug Discov. 2014;13:813–27.
6. Allen LV. Pharmaceutical dosage forms. New York: Marcel Dekker; 2008.
7. Dressman JB, Reppas C. In vitro–in vivo correlations. Eur J Pharm Sci. 2000;11:S73–80.
8. Lennernäs H. Human intestinal permeability. J Pharm Sci. 1998;87:403–10.
9. Mahato RI. Pharmaceutical dosage forms and drug delivery. Boca Raton: CRC Press; 2012.
10. Jain NK. Controlled and novel drug delivery. New Delhi: CBS Publishers; 2014.
11. Hadgraft J. Skin, the final frontier. Int J Pharm. 2001;224:1–18.
12. Park K. Controlled drug delivery systems. J Control Release. 2014;190:3–8.
13. Siepmann J, Siepmann F. Modeling of drug release. Int J Pharm. 2008;364:328–43.
14. Dash AK, Cudworth GC. Therapeutic applications of implantable DDS. J Pharmacol Toxicol Methods. 1998;40:1–12.
15. Costa P, Sousa Lobo JM. Modeling of drug release. Eur J Pharm Sci. 2001;13:123–33.

16. Allen TM. Ligand-targeted therapeutics. Nat Rev Cancer. 2002;2:750–63.
17. Maeda H. Tumor-selective delivery. Adv Drug Deliv Rev. 2015;91:3–6.
18. Torchilin VP. Targeted pharmaceutical nanocarriers. Pharm Res. 2007;24:1–16.
19. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology. Nat Commun. 2014;5:1–12.
20. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–8.
21. Barry BW. Breaching the skin's barrier. Nat Biotechnol. 2004;22:165–7.
22. Ita K. Transdermal delivery: progress and challenges. J Drug Deliv Sci Technol. 2014;24:245–50.
23. Patton JS, Byron PR. Inhaling medicines. Nat Rev Drug Discov. 2007;6:67–74.
24. Labiris NR, Dolovich MB. Pulmonary DDS. Br J Clin Pharmacol. 2003;56:588–99.
25. Hickey AJ. Inhalation aerosol technology. Boca Raton: CRC Press; 2013.
26. Urtti A. Challenges in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58:1131–5.
27. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular DDS. AAPS J. 2010;12:348–60.
28. Friend DR. Colon-targeted DDS. Adv Drug Deliv Rev. 1991;7:149–99.
29. Andrews GP, Laverty TP, Jones DS. Mucoadhesive DDS. Eur J Pharm Biopharm. 2009;71:505–18.
30. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems. Chem Rev. 1999;99:3181–98.
31. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery. Annu Rev Med. 2012;63:185–98.
32. Kesharwani P, Jain NK. Dendrimer as nanocarrier. Prog Polym Sci. 2014;39:268–307.
33. Irvine DJ, Swartz MA, Szeto GL. Engineering vaccines. Nat Mater. 2013;12:978–90.
34. Moghimi SM, Hunter AC, Murray JC. Nanomedicine challenges. FASEB J. 2005;19:311–30.
35. Sant S, Johnston PA. Future of DDS. J Control Release. 2017;253:1–2.
36. Kreuter J. Nanoparticles. Int J Pharm. 2007;331:1–10.
37. Immordino ML, Dosio F, Cattel L. Stealth liposomes. Int J Nanomedicine. 2006;1:297–315.
38. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable nanoparticles. J Control Release. 2001;70:1–20.
39. Chauhan AS. Dendrimers. Mol Pharm. 2008;5:590–600.
40. Kwon GS. Polymeric micelles. Crit Rev Ther Drug Carrier Syst. 2003;20:357–403.

41. Zhang XQ, Xu X, Lam R, Giljohann D, Ho D, Mirkin CA. Nanoparticles in medicine. ACS Nano. 2011;5:6962–70.
42. Duncan R. Polymer conjugates. Nat Rev Drug Discov. 2003;2:347–60.
43. Mura S, Nicolas J, Couvreur P. Stimuli-responsive DDS. Nat Mater. 2013;12:991–1003.
44. Qiu Y, Park K. Environment-sensitive hydrogels. Adv Drug Deliv Rev. 2012;64:49–60.
45. Alvarez-Lorenzo C, Concheiro A. Smart hydrogels. Chem Commun. 2014;50:7743–65.
46. Rwei AY, Wang W, Kohane DS. Photoresponsive DDS. Nano Today. 2015;10:451–67.
47. Park K. DDS at a crossroads. J Control Release. 2014;190:3–8.
48. Plotkin S. Vaccines: past, present and future. Nat Med. 2005;11:S5–11.
49. Foged C, Hansen J, Agger EM. Vaccine nanocarriers. Expert Rev Vaccines. 2012;11:561–77.
50. Prausnitz MR. Microneedles for vaccination. Curr Opin Pharmacol. 2015;22:1–7.
51. Holmgren J, Czerkinsky C. Mucosal immunity. Nat Med. 2005;11:S45–53.
52. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines. Nat Rev Drug Discov. 2018;17:261–79.
53. Pardridge WM. BBB drug delivery. NeuroRx. 2005;2:3–14.
54. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Brain targeting DDS. J Control Release. 2016;235:34–47.
55. Illum L. Nasal drug delivery. J Control Release. 2003;87:187–98.
56. Patel MM, Patel BM. Crossing the BBB. CNS Drugs. 2017;31:109–33.
57. FDA. Guidance for industry: Nanotechnology. Silver Spring: FDA; 2014.
58. EMA. Reflection paper on nanotechnology-based medicinal products. London: EMA; 2011.
59. Yu LX. Pharmaceutical QbD. AAPS J. 2008;10:405–7.
60. DiMasi JA, Grabowski HG, Hansen RW. Innovation cost. J Health Econ. 2016;47:20–33.
61. Fadeel B, Garcia-Bennett AE. Better safe than sorry. Adv Drug Deliv Rev. 2010;62:362–74.
62. World Health Organization. Access to medicines. Geneva: WHO; 2017.
63. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. AI in DDS. Drug Discov Today. 2021;26:80–93.
64. Norman J, Madurawe RD, Moore CMV, Khan MA, Khairuzzaman A. 3D printing. AAPS J. 2017;19:1–13.